Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 3, March, p. 379–382

doi: 10.17219/acem/68291

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

β2-microglobulin as a marker of systemic lupus erythematosus activity

Iwona Żychowska1,A,B,C,D, Dorota Suszek1,B,C,D, Magdalena Dryglewska1,B,D, Maria Majdan1,E,F

1 Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Poland


Background. Systemic lupus erythematosus (SLE) is characterized by alternating periods of activity and remission. A portion of the patients suffers from the chronically active form of the disease. The search for clinically useful markers of its activity is ongoing. At present, it is suggested that β2-microglobulin (β2M) may be useful in assessing SLE activity.
Objectives. The objective of the paper was to investigate the relationship between serum β2M concentration and SLE activity.
Material and Methods. The study group consisted of 69 SLE patients (62 women and 7 men), aged 34.5 ±11 years (19–69). Patients with kidney failure and infection were excluded from the study group. The concentration of β2M was measured using an ELISA test. SLE activity was assessed with Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and by measuring the levels of C3 and C4 complement components, anti-double stranded DNA antibodies (anti-dsDNA antibodies) and β2M. The relationship between β2M and the clinical manifestation of SLE was also covered in the study.
Results. The study revealed a statistically significant correlation between β2M concentration and SLEDAI-2K disease activity index (p < 0.05; r = 0.6), anti-dsDNA titer (p < 0.05; r = 0.3), and C4 component serum level (p < 0.05; r = −0.3). β2M concentration was significantly higher in patients with arthritis and/or myositis (p = 0.005), vasculitis (p = 0.005), and hematological manifestations of SLE (p = 0.02).
Conclusion. Periodical determination of β2M concentration in SLE patients may prove helpful in assessing the disease activity.

Key words

systemic lupus erythematosus, disease activity, β2-microglobulin

References (16)

  1. Kyttaris VC, Krishnan S, Tsokos GC. Systems biology in systemic lupus erythematosus: Integrating genes, biology and immune function. Autoimmunity. 2006;39:705–709.
  2. Gladman DD, Ibenz D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol. 2002;29:288–291.
  3. Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. Definition and treatment lupus flares measured by the BILAG index. Rheumatology. 2003;42:1372–1379.
  4. Trendelenburg M. Antibodies against C1q in patients with systemic lupus erythematosus. Springer Semin Immunopathol. 2005;27:276–285.
  5. Smykał-Jankowiak K, Niemir ZI, Polcyn-Adamczak M. Do circulating antibodies against C1q reflect the activity of lupus nephritis? Pol Arch Med Wewn. 2011;121:287–295.
  6. Olesińska M, Chwalińska-Sadowska H, Wiesik-Szewczyk E, Mielnik P, Zabek J. Clinical manifestation of systemic lupus erythematosus in patients with antiribosomal P protein antibodies. Pol Arch Med Wewn. 2010;120:76–81.
  7. Nielepkowicz-Goździńska A, Fendler W, Robak E, et al. Exhaled cytokines in systemic lupus erythematosus with lung involvement. Pol Arch Med Wewn. 2013;123:141–148.
  8. Evrin PE, Strom T. Beta 2-microglobulin and its binding activity in serum from patients with SLE. Ann Rheum Dis. 1984;43:267–274.
  9. Bień E, Balcerska A. Znaczenie kliniczne β2-mikroglobuliny w chorobie nowotworowej u dorosłych i dzieci. Współcz Onkol. 2003;7:333–338.
  10. Kim HA, Jeon JY, Yoon JM, Suh CH. Beta 2-microglobulin can be a disease activity marker in systemic lupus erythematosus. Am J Med Sci. 2010;339:337–340.
  11. Hermansen ML, Hummelshøj L, Lundsgaard D, et al. Increased serum β2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus. Lupus. 2012;21:1098–1104.
  12. Skare TL, Ferri K, Santos MA. Systemic lupus erythematosus activity and beta two microglobulin levels. Sao Paulo Med J. 2014;132:239–242.
  13. Wakabayashi K, Inokuma S, Matsubara E, et al. Serum β2-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adult-onset Still’s disease. Clin Rheumatol. 2013;32:999–1005.
  14. Ooi BS, Ooi YM, Pesce AJ, Pollak VE. Antibodies to beta 2-microglobulin in the sera of patients with systemic lupus erythematosus. Immunology. 1977;33:535–341.
  15. Revillard JP, Vincent C, Rivera S. Anti-beta2-microglobulin lymphocytoxic autoantibodies in systemic lupus erythematosus. J Immunol. 1979;122:614–618.
  16. Chan OT, Paliwal V, McNiff JM, Park SH, Bendelac A, Shlomchik MJ. Deficiency in beta2-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas (lpr) mice: An example of disease regulation at the organ level. J Immunol. 2001;167:2985–2990.